Informations relatives au nombre total de droits de vote et d’actions composant le capital
Filed with Euronext · · 1 page · French
Summary by 6ix AI
This filing from OSE Immunotherapeutics SA provides information regarding the total number of voting rights and shares comprising its capital as of a specific date. It complies with relevant regulations and informs shareholders about the company's capital structure. The document also includes a brief overview of OSE Immunotherapeutics and its focus on developing first-in-class therapies in immuno-oncology and immuno-inflammation.
Written in English by 6ix AI from the company’s French-language filing. How 6ix writes summaries
OSE Immunotherapeutics SA on 6ix
Earlier from OSE Immunotherapeutics
- OSE Immunotherapeutics Reports its Cash Position as of June 30, 2026, and Provides Business Update
- OSE Immunotherapeutics Announces Presentation of Combi-TED Phase 2 Topline Results of Tedopi® in Non-Small Cell Lung Cancer at the ESMO 2026 Meeting
- OSE Immunotherapeutics annonce la présentation des principaux résultats de l'étude de Phase 2 Combi-TED de Tedopi® dans le cancer du poumon non à petites cellules au Congrès 2026 de l’ESMO
- OSE Immunotherapeutics Welcomes First Patient Dosed by Veloxis in the Phase 2 RENGEVITY-201 Trial Evaluating Pegrizeprument (VEL-101) for the Prevention of Organ Rejection in Kidney Transplant Recipients
- OSE Immunotherapeutics se félicite de l’inclusion du premier patient traité par Veloxis dans l’étude de phase 2 RENGEVITY-201 évaluant le pegrizeprument (VEL-101) dans la prévention du rejet d’organe chez les patients transplantés rénaux
Later from OSE Immunotherapeutics
- OSE Immunotherapeutics to Present at Chardan’s 10th Annual Healthcare Conference
- OSE Immunotherapeutics Reports Positive Topline Results of Combi-TED Phase 2 Randomized Trial with Tedopi® (OSE2101) in metastatic Non-Small Cell Lung Cancer
Follow OSE Immunotherapeutics into a list and get an email when it puts out news.
Follow OSE Immunotherapeutics